FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)

View source ↗

Summary

FDA supplemental approval application submitted for TYSABRI (natalizumab) by Biogen; seeks regulatory action on an additional indication or labeling change.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

SUPPL AP for TYSABRI (NATALIZUMAB)